Bibliographic Details
| Title: |
Pregnant Woman in Outcomes with Prosthetic Heart Valves |
| Authors: |
Giunai Sefiyeva, Ulyana Shadrina, Tatiana Vavilova, Olga Sirotkina, Andrey Bautin, Aigul Chynybekova, Anna Pozhidaeva, Ekaterina Stepanovykh, Anna Starshinova, Dmitry Kudlay, Olga Irtyuga |
| Source: |
Journal of Cardiovascular Development and Disease, Vol 11, Iss 11, p 353 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
pregnant woman, prosthetic heart valves, mechanical valve prostheses, biological valve prosthesis, anti-factor Xa, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
We here sought to assess thrombotic and hemorrhagic complications and associated risk factors during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV). Methods: The retrospective cohort study covered January 2011 to December 2022. The objective of the study was to assess the risk factors and frequency of thrombotic and hemorrhagic complications during pregnancy, delivery, and the postpartum period in women with PHV based on the experience of one perinatal center. We included 88 pregnancies with 77 prosthetic heart valves (PHV), which were divided into two groups, mechanical valve prostheses (MVP) (n = 64) and biological valve prosthesis (BVP) (n = 24). In the study we analyzed pregnancy outcomes, as well as thrombotic and hemorrhagic complication frequencies. Results: Of 88 pregnancies, 79 resulted in live births. In the MVP group, there were six miscarriages (9.4%) and two medical abortions (3.1%), including one due to Warfarin’s teratogenic effects. No miscarriages were reported in the BVP group, but one fetal mortality case (4.2%) occurred. During pregnancy, 11 MVP cases (17.2%) experienced thrombotic complications. In the BVP group, one patient (4.2%) had transient ischemic attack (TIA). Two MVP cases required surgical valve repair during pregnancy, and one in the post-delivery stage was caused by thrombotic complications. Postpartum, two MVP cases had strokes, and in one MVP patient, pulmonary embolism was registered, while no thrombotic complications occurred in the BVP group. Hemorrhagic complications affected 15 MVP cases (17.9%) in the postpartum period. There were no registered cases of maternal mortality. Conclusions: The effective control of anti-factor Xa activity reduced thrombotic events. However, the persistently high incidence of postpartum hemorrhagic complications suggests a need to reassess anticoagulant therapy regimens, lower target levels of anti-Xa, and reduce INR levels for discontinuing heparin bridge therapy. Despite the heightened mortality risk in MVP patients, our study cohort did not have any mortality cases, which contrasts with findings from other registries. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2308-3425 |
| Relation: |
https://www.mdpi.com/2308-3425/11/11/353; https://doaj.org/toc/2308-3425 |
| DOI: |
10.3390/jcdd11110353 |
| Access URL: |
https://doaj.org/article/fc16a64ba80a4203b7c5bb9614587a26 |
| Accession Number: |
edsdoj.fc16a64ba80a4203b7c5bb9614587a26 |
| Database: |
Directory of Open Access Journals |
